IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 55.82

Change

-0.04 (-0.07)%

Market Cap

N/A

Volume

0.41M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.18 (-0.14%)

USD 33.98B
FHLC Fidelity® MSCI Health Care In..

-0.05 (-0.08%)

USD 2.37B
FXH First Trust Health Care AlphaD..

-0.08 (-0.08%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

+0.43 (+0.53%)

USD 0.17B
IDNA iShares Genomics Immunology an..

-0.11 (-0.53%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.06 (-0.06%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.09 (+0.29%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.12 (-0.44%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.20 (+0.34%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.18 (+0.91%)

USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.20% 40% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.20% 40% F 30% F
Trailing 12 Months  
Capital Gain -8.84% 29% F 24% F
Dividend Return 0.91% 81% B- 19% F
Total Return -7.92% 33% F 21% F
Trailing 5 Years  
Capital Gain 26.32% 81% B- 53% F
Dividend Return 6.88% 74% C 17% F
Total Return 33.20% 81% B- 45% F
Average Annual (5 Year Horizon)  
Capital Gain 3.79% 76% C+ 53% F
Dividend Return 4.78% 76% C+ 48% F
Total Return 0.99% 79% B- 22% F
Risk Return Profile  
Volatility (Standard Deviation) 17.40% 48% F 55% F
Risk Adjusted Return 27.46% 71% C- 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.